Assessment of Total, PTEN

Benzamides Biomarkers, Tumor Flow Cytometry Humans Male Neoplastic Cells, Circulating Nitriles PTEN Phosphohydrolase / genetics Phenylthiohydantoin Prospective Studies Prostatic Neoplasms, Castration-Resistant / drug therapy Protein Isoforms Receptors, Androgen
Abiraterone Hormonal therapy LHRH agonist Liquid biopsy MDV3100

Journal

Clinical genitourinary cancer
ISSN: 1938-0682
Titre abrégé: Clin Genitourin Cancer
Pays: United States
ID NLM: 101260955

Informations de publication

Date de publication:
10 2021
Historique:
received: 17 01 2021
revised: 22 03 2021
accepted: 27 03 2021
pubmed: 8 5 2021
medline: 25 2 2023
entrez: 7 5 2021
Statut: ppublish

Résumé

Metastatic castration-resistant prostate cancer (mCRPC) is a deadly disease. Enzalutamide is an oral second-generation anti-androgen that is active in mCRPC. Circulating tumor cells (CTC) count correlates with overall survival (OS) in mCRPC, whereas detection of the androgen-receptor splice variant 7 (AR-V7) in CTC predicts poor response to oral second-generation anti-androgens. Also, loss of PTEN (phosphatase and tensin homolog) in CTC is a biomarker of poor prognosis in mCRPC. In this translational study, we employed flow cytometry to assess total, PTEN CTCs were assessed in a total of 45 men with mCRPC at baseline and at 12 weeks. Overall, CTC, PTEN Despite multiple limitations, including the small sample size, our preliminary study suggests that assessment of CTC via flow cytometry may provide potentially useful prognostic and predictive information in advanced prostate cancer. Further studies are warranted. Micro-Abstract: In this study, men with metastatic castration-resistant prostate cancer, scheduled to start enzalutamide, were assessed for circulating tumor cell count and molecular characterization (total, PTEN

Identifiants

DOI: 10.1016/j.clgc.2021.03.021 PMID: 33958297
pubmed: 33958297
pii: S1558-7673(21)00084-7
doi: 10.1016/j.clgc.2021.03.021
pii:
doi:

Substances chimiques

Benzamides 0
Biomarkers, Tumor 0
Nitriles 0
Protein Isoforms 0
Receptors, Androgen 0
Phenylthiohydantoin 2010-15-3
enzalutamide 93T0T9GKNU
PTEN Phosphohydrolase EC 3.1.3.67
PTEN protein, human EC 3.1.3.67

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e286-e298

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Giuseppe Di Lorenzo (G)

Department of Clinical Medicine and Surgery, University Federico II of Naples, Naples, Italy; Department of Medicine and Health Sciences "Vincenzo Tiberio," University of Molise, Campobasso, Italy; Department of Oncology, Hospital "Andrea Tortora," ASL Salerno, Pagani, Italy; Department of Oncology and Hematology, AOU Federico II of Naples, Naples, Italy.

Silvia Zappavigna (S)

Department of Precision Medicine, University of Campania "L. Vanvitelli," Naples, Italy.

Felice Crocetto (F)

Department of Neurosciences, Human Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy.

Mario Giuliano (M)

Department of Clinical Medicine and Surgery, University Federico II of Naples, Naples, Italy; Regional Reference Center for Rare Tumors, Department of Oncology and Hematology, AOU Federico II of Naples, Naples, Italy.

Dario Ribera (D)

Department of Clinical Medicine and Surgery, University Federico II of Naples, Naples, Italy.

Rocco Morra (R)

Department of Clinical Medicine and Surgery, University Federico II of Naples, Naples, Italy.

Luca Scafuri (L)

Department of Clinical Medicine and Surgery, University Federico II of Naples, Naples, Italy.

Antonio Verde (A)

Department of Clinical Medicine and Surgery, University Federico II of Naples, Naples, Italy.

Dario Bruzzese (D)

Department of Public Health, University of Naples "Federico II," Naples, Italy.

Simona Iaccarino (S)

Department of Clinical Medicine and Surgery, University Federico II of Naples, Naples, Italy.

Ferdinando Costabile (F)

Department of Clinical Medicine and Surgery, University Federico II of Naples, Naples, Italy.

Livia Onofrio (L)

Department of Clinical Medicine and Surgery, University Federico II of Naples, Naples, Italy.

Martina Viggiani (M)

Department of Clinical Medicine and Surgery, University Federico II of Naples, Naples, Italy.

Alessandro Palmieri (A)

Department of Neurosciences, Human Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy.

Pietro De Placido (P)

Department of Clinical Medicine and Surgery, University Federico II of Naples, Naples, Italy.

Antonella Lucia Marretta (AL)

Department of Clinical Medicine and Surgery, University Federico II of Naples, Naples, Italy.

Erica Pietroluongo (E)

Department of Clinical Medicine and Surgery, University Federico II of Naples, Naples, Italy.

Amalia Luce (A)

Department of Precision Medicine, University of Campania "L. Vanvitelli," Naples, Italy.

Marianna Abate (M)

Department of Precision Medicine, University of Campania "L. Vanvitelli," Naples, Italy.

Zahrasadat Navaeiseddighi (Z)

Department of Precision Medicine, University of Campania "L. Vanvitelli," Naples, Italy.

Vincenzo Francesco Caputo (VF)

Department of Neurosciences, Human Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy.

Giuseppe Celentano (G)

Department of Neurosciences, Human Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy.

Nicola Longo (N)

Department of Neurosciences, Human Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy.

Matteo Ferro (M)

Division of Urology, European Institute of Oncology-IRCCS, Milan, Italy.

Franco Morelli (F)

Medical Oncology Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.

Gaetano Facchini (G)

Departmental Unit of Experimental Uro-Andrological Clinical Oncology, Department of Uro-Gynaecological Oncology, National Cancer Institute-IRCCS-G. Pascale Foundation, Naples, Italy.

Michele Caraglia (M)

Department of Precision Medicine, University of Campania "L. Vanvitelli," Naples, Italy; Biogem Scarl, Institute of Genetic Research, Laboratory of Precision Medicine and Molecular Oncology, Ariano Irpino, Italy.

Sabino De Placido (S)

Department of Clinical Medicine and Surgery, University Federico II of Naples, Naples, Italy; Regional Reference Center for Rare Tumors, Department of Oncology and Hematology, AOU Federico II of Naples, Naples, Italy.

Carlo Buonerba (C)

Department of Clinical Medicine and Surgery, University Federico II of Naples, Naples, Italy; Regional Reference Center for Rare Tumors, Department of Oncology and Hematology, AOU Federico II of Naples, Naples, Italy. Electronic address: carlo.buonerba@unina.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Hydrocarbures cycliques › Hydrocarbures aromatiques › Dérivés du benzène › Benzoates › Benzamides › Assessment of Total, PTEN
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Assessment of Total, PTEN
questionsmedicales.fr › Techniques d'investigation › Techniques cytologiques › Cytophotométrie › Cytométrie en flux › Assessment of Total, PTEN
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Assessment of Total, PTEN
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Métastase tumorale › Cellules tumorales circulantes › Assessment of Total, PTEN
questionsmedicales.fr › Composés chimiques organiques › Nitriles › Assessment of Total, PTEN
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines suppresseurs de tumeurs › Phosphohydrolase PTEN › Assessment of Total, PTEN
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Azoles › Imidazoles › Imidazolidines › Hydantoïnes › Thiohydantoïnes › 3-Phényl-2-thiohydantoïne › Assessment of Total, PTEN
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Assessment of Total, PTEN
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs de la prostate › Tumeurs prostatiques résistantes à la castration › Assessment of Total, PTEN
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Isoformes de protéines › Assessment of Total, PTEN
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Récepteurs cytoplasmiques et nucléaires › Récepteurs aux androgènes › Assessment of Total, PTEN